Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.
Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.